JPMorgan Chase & Co. Has $54.65 Million Stock Position in Glaukos Corporation $GKOS

JPMorgan Chase & Co. increased its holdings in Glaukos Corporation (NYSE:GKOS) by 4.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 670,083 shares of the medical instruments supplier’s stock after acquiring an additional 27,646 shares during the period. JPMorgan Chase & Co. owned about 1.17% of Glaukos worth $54,645,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of GKOS. AustralianSuper Pty Ltd boosted its position in Glaukos by 10.8% during the third quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock valued at $36,685,000 after purchasing an additional 43,750 shares during the last quarter. Riverbridge Partners LLC increased its position in Glaukos by 41.0% in the 3rd quarter. Riverbridge Partners LLC now owns 569,644 shares of the medical instruments supplier’s stock worth $46,454,000 after purchasing an additional 165,673 shares during the last quarter. Holocene Advisors LP raised its stake in shares of Glaukos by 40.1% during the 2nd quarter. Holocene Advisors LP now owns 1,045,886 shares of the medical instruments supplier’s stock worth $108,030,000 after purchasing an additional 299,118 shares in the last quarter. TD Asset Management Inc purchased a new stake in shares of Glaukos during the 3rd quarter worth about $1,157,000. Finally, Public Sector Pension Investment Board lifted its holdings in shares of Glaukos by 14.8% during the 3rd quarter. Public Sector Pension Investment Board now owns 223,708 shares of the medical instruments supplier’s stock valued at $18,243,000 after buying an additional 28,866 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Glaukos

In related news, CEO Thomas William Burns sold 186,945 shares of the business’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $115.00, for a total transaction of $21,498,675.00. Following the completion of the transaction, the chief executive officer owned 153,775 shares of the company’s stock, valued at approximately $17,684,125. The trade was a 54.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Aimee S. Weisner sold 15,000 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $117.38, for a total value of $1,760,700.00. Following the sale, the director owned 18,806 shares of the company’s stock, valued at approximately $2,207,448.28. The trade was a 44.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 320,625 shares of company stock valued at $37,264,878. 5.80% of the stock is owned by corporate insiders.

Glaukos Trading Down 1.3%

NYSE:GKOS opened at $100.81 on Friday. The company’s 50 day moving average is $113.46 and its 200-day moving average is $101.41. The company has a quick ratio of 4.06, a current ratio of 4.69 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $130.23. The firm has a market cap of $5.85 billion, a price-to-earnings ratio of -30.92 and a beta of 0.70.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The firm had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.Glaukos’s quarterly revenue was up 35.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.40) earnings per share. Equities analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on GKOS shares. Citigroup increased their price objective on Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, January 22nd. UBS Group increased their price target on shares of Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, December 23rd. Wells Fargo & Company raised their price target on shares of Glaukos from $122.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Finally, BTIG Research reiterated a “buy” rating and issued a $131.00 price objective on shares of Glaukos in a report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and an average target price of $133.69.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.